The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement

This announcement, for which the directors (the "Directors") of Sino Biopharmaceutical Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading; there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.



## SINO BIOPHARMACEUTICAL LIMITED

## 中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

## ANNOUNCEMENT ON A CHANGE OF CORPORATE STATUS OF A PRC SUBSIDIARY

The board of Directors is pleased to announce that MOFTEC approved the application for conversion of CTT into a sino-foreign equity joint stock limited company known as JCTT.

Reference is made to the announcement (the "Announcement") of the Company dated 7 December, 2001 in respect of an application to MOFTEC for a proposed change of corporate status of a subsidiary of the Company in the PRC. Terms used herein shall have the same meaning as defined in the Announcement.

The board of Directors is pleased to announce that such application was approved by MOFTEC on 19 December, 2001 and CTT is applying to the State Industry and Commerce Administration Bureau of the PRC for a revised business licence which is expected to be issued around 24 December, 2001. Upon the issue of such revised business licence, the conversion of the sino-foreign equity joint venture company with limited liability established in the PRC known as CTT into a sino-foreign equity joint stock limited

company known as JCTT will become effective. Following the conversion, all assets, liabilities and contractual rights and obligations of CTT will continue to be undertaken and assumed by JCTT and the Company will continue to hold 60% of the issued share capital of JCTT through CTL.

On behalf of the Board
Sino Biopharmaceutical Limited
Tse Ping
Chairman

Hong Kong, 21 December, 2001

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least seven days from the day of its posting.